Acne is a common and clinically relevant adverse event among patients with IBD receiving JAK inhibitors. Acne occurs in 8.6% of individuals with inflammatory bowel diseases (IBD) who are receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results